Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter.
Read more